Marc Riedl, M.D.

Edit your Faculty Profile
Work Titles
UCLA Associate Professor, Medicine Section Head, Clinical Immunology and Allergy
Education:
Degrees:
M.D., University of Chicago Pritzker School of Medicine, 1998
M.S., UCLA School of Medicine, 2004
Fellowship:
2004 UCLA School of Medicine
2001 - 2003 UCLA School of Medicine
Internship:
1998 - 1999 Washington University School of Medicine
Residency:
1999 - 2001 Washington University School of Medicine
Certifications:
Certifications:
2003 American Board of Allergy and Immunology
2001 American Board of Internal Medicine

Contact Information:

Email Address:

mriedl@mednet.ucla.edu


Website:

Web-Profile

Work Phone Number:

(310) 825-6011

Mailing Address:

Practice Location
200 UCLA Medical Plaza, Suite 365
Los Angeles, CA 90095


Research Interest:

Biography

Marc Riedl is an Associate Professor of Medicine and Section Head of Clinical Immunology and Allergy at the UCLA David Geffen School of Medicine. He received his medical degree from the University of Chicago-Pritzker School of Medicine, completed a residency in internal medicine at Barnes-Jewish Hospital of Washington University in St. Louis, and a fellowship in Clinical Immunology and Allergy at UCLA. Dr. Riedl received a Master of Science Degree in Clinical Research and completed advanced training in Clinical Pharmacology at UCLA. His professional interests include the development of novel therapeutics for the treatment of allergic and immunodeficient conditions. His research currently focuses on the treatment of Hereditary Angioedema and Common Variable Immunodeficiency. Dr. Riedl is involved in the development of investigational drugs including compounds to reduce respiratory inflammation caused by air pollution.

Detailed Biography:

Marc Riedl is an Associate Professor of Medicine and Section Head of Clinical Immunology and Allergy at the UCLA David Geffen School of Medicine. He received his medical degree from the University of Chicago-Pritzker School of Medicine, completed a residency in internal medicine at Barnes-Jewish Hospital of Washington University in St. Louis, and a fellowship in Clinical Immunology and Allergy at UCLA. Dr. Riedl received a Master of Science Degree in Clinical Research and completed advanced training in Clinical Pharmacology at UCLA. His professional interests include the development of novel therapeutics for the treatment of allergic and immunodeficient conditions. His research currently focuses on the treatment of Hereditary Angioedema and Common Variable Immunodeficiency. Dr. Riedl is involved in the development of investigational drugs including compounds to reduce respiratory inflammation caused by air pollution.

Publications:

A selected list of publications:

Lumry William R, Bernstein Jonathan A, Li H Henry, MacGinnitie Andrew J, Riedl Marc, Soteres Daniel F, Craig Timothy J, Campion Marilyn, Iarrobino Ryan, Stolz Leslie E, Pullman William E   Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2013; 34(2): 155-61.
Riedl Marc A, Levy Robyn J, Suez Daniel, Lockey Richard F, Baker James W, Relan Anurag, Zuraw Bruce L   Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013; 110(4): 295-9.
Baker James W, Craig Timothy J, Riedl Marc A, Banerji Aleena, Fitts David, Kalfus Ira N, Uknis Marc E   Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2013; 34(2): 162-9.
Li H Henry, Campion Marilyn, Craig Timothy J, Soteres Daniel F, Riedl Marc, Lumry William R, MacGinnitie Andrew J, Shea Elizabeth P, Bernstein Jonathan A   Analysis of hereditary angioedema attacks requiring a second dose of ecallantide Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013; 110(3): 168-72.
Geng Bob, Riedl Marc A   HAE update: special considerations in the female patient with hereditary angioedema Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2013; 34(1): 13-8.
Zuraw Bruce L, Bork Konrad, Binkley Karen E, Banerji Aleena, Christiansen Sandra C, Castaldo Anthony, Kaplan Allen, Riedl Marc, Kirkpatrick Charles, Magerl Markus, Drouet Christian, Cicardi Marco   Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2013; 33 Suppl 1(1): S145-56.
Kalfus Ira N, Gower Richard Glen, Riedl Marc, Bernstein Jonathan A, Lumry William R, Frank Michael M   Hereditary angioedema: implications of treating a rare disease Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012; 109(2): 150-1; author reply 151.
Riedl Marc   Hereditary angioedema therapies in the United States: movement toward an international treatment consensus Clinical therapeutics, 2012; 34(3): 623-30.
Riedl Marc A, Diaz-Sanchez David, Linn William S, Gong Henry, Clark Kenneth W, Effros Richard M, Miller J Wayne, Cocker David R, Berhane Kiros T, Berhane Kiros T   Allergic inflammation in the human lower respiratory tract affected by exposure to diesel exhaust Research report (Health Effects Institute), 2012; 34(165): 5-43; discussion 45-64.
Riedl Marc A, Hurewitz David S, Levy Robyn, Busse Paula J, Fitts David, Kalfus Ira   Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2012; 108(1): 49-53.
Lumry William R, Li H Henry, Levy Robyn J, Potter Paul C, Farkas Henriette, Moldovan Dumitru, Riedl Marc, Li Hongbin, Craig Timothy, Bloom Bradley J, Reshef Avner   Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011; 107(6): 529-37.
Toscani Michael, Riedl Marc   Meeting the challenges and burdens associated with hereditary angioedema Managed care (Langhorne, Pa.), 2011; 20(9): 44-51.
Parikh Neil, Riedl Marc A   New therapeutics in C1INH deficiency: a review of recent studies and advances Current allergy and asthma reports, 2011; 11(4): 300-8.
Riedl Marc, Gower Richard G, Chrvala Carole Alison   Current medical management of hereditary angioedema: results from a large survey of US physicians Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2011; 106(4): 316-322.e4.
Riedl Marc A   Update on the acute treatment of hereditary angioedema Allergy and asthma proceedings : the official journal of regional and state allergy societies, 2011; 32(1): 11-6.
Riedl Marc, Campion Marilyn, Horn Patrick T, Pullman William E   Response time for ecallantide treatment of acute hereditary angioedema attacks Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2010; 105(6): 430-436.e2.
Riedl Marc   Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism The World Allergy Organization journal, 2010; 3(9 Suppl): S34-8.
Zuraw Bruce L, Frank Michael M, Riedl Marc A   Introduction: New Perspectives in Hereditary Angioedema (HAE): Molecular Mechanisms & Therapeutic Choices: A CME Symposium Presented at the 2009 World Allergy Congress, Buenos Aires, Argentina, December 9, 2009 The World Allergy Organization journal, 2010; 3(9 Suppl): S24.
Braskett Melinda, Riedl Marc A   Novel antioxidant approaches to the treatment of upper airway inflammation Current opinion in allergy and clinical immunology, 2010; 10(1): 34-41.
Lin Erina, Saxon Andrew, Riedl Marc   Penicillin allergy: value of including amoxicillin as a determinant in penicillin skin testing International archives of allergy and immunology, 2010; 152(4): 313-8.
Craig Timothy, Riedl Marc, Dykewicz Mark S, Gower Richard G, Baker James, Edelman Frank J, Hurewitz David, Jacobs Joshua, Kalfus Ira   When is prophylaxis for hereditary angioedema necessary? Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009; 102(5): 366-72.
Riedl Marc A, Saxon Andrew, Diaz-Sanchez David   Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway Clinical immunology (Orlando, Fla.), 2009; 130(3): 244-51.
Riedl Marc A   The effect of air pollution on asthma and allergy Current allergy and asthma reports, 2008; 8(2): 139-46.
Riedl Marc A, Nel Andre E   Importance of oxidative stress in the pathogenesis and treatment of asthma Current opinion in allergy and clinical immunology, 2008; 8(1): 49-56.
Wertman Brett, Azarbal Babak, Riedl Marc, Tobis Jonathan   Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure Journal of the American College of Cardiology, 2006; 47(6): 1226-7.
Riedl Marc A, Landaw Elliot M, Saxon Andrew, Diaz-Sanchez David   Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen Journal of immunology (Baltimore, Md. : 1950), 2005; 174(11): 7440-5.
Riedl Marc, Diaz-Sanchez David   Biology of diesel exhaust effects on respiratory function The Journal of allergy and clinical immunology, 2005; 115(2): 221-8; quiz 229.
Riedl Marc A, Casillas Adrian M   Adverse drug reactions: types and treatment options American family physician, 2003; 68(9): 1781-90.

Does this profile need updating? Contact Us